Hepatitis B virus (HBV) reactivation after allogeneic haematopoietic stem cell transplantation (allo-HSCT) is well known in HBsAg-positive carriers but has only occasionally been reported in patients with resolved HBV infection. We investigated six allo-HSCT recipients with pretransplant anti-HBs and anti-HBc antibodies for serologic markers of HBV infection and for the presence of HBV-DNA in serum. Reverse seroconversion, that is, reappearance of HBsAg after a gradual loss of anti-HBs, but no severe liver damage was observed in three patients at 14, 22 and 12 months after HSCT, respectively. There was an increase in HBV-DNA concentration prior to reverse seroconversion. One patient was repeatedly HBV-DNA positive (10 2 -10 3 copies/ml) without reverse seroconversion. Sequencing of the HBsAg and precore region derived from the four HBV-DNA-positive patients showed no relevant mutations. In conclusion, this study demonstrated a high risk (50%) of reverse seroconversion in allo-HSCT recipients with resolved HBV infection. A highly sensitive HBV-DNA assay (TaqMan-PCR) allowed early identification of the individual patients at risk. Reactivation of HBV is a well-known complication in patients with chronic hepatitis B virus (HBV) infection undergoing immunosuppressive or cytotoxic therapy. HBsAg-positive recipients of haematopoietic stem cell transplantation (HSCT) have a higher incidence of clinical hepatitis associated with HBV reactivation, most often during immunological recovery.
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Reactivation of HBV is a well-known complication in patients with chronic hepatitis B virus (HBV) infection undergoing immunosuppressive or cytotoxic therapy. HBsAg-positive recipients of haematopoietic stem cell transplantation (HSCT) have a higher incidence of clinical hepatitis associated with HBV reactivation, most often during immunological recovery. 1 The proposed mechanism is an increase in viral replication in the liver during the period of immunosuppression, followed by an immune mediated destruction of infected hepatocytes after cessation of immunosuppressive therapy. The risk of fatal HBV liver disease among patients who are persistently HBsAg positive after HSCT is approximately 12%. 2 HBV reactivation has also been observed in HBsAgnegative HSCT recipients with antibodies against HBs and HBc antigens (anti-HBs and anti-HBc, respectively), that is, in patients with resolved HBV infection. Therefore, the presence of these antibodies does not necessarily reflect viral clearance. In individuals with resolved infection, HBV has been shown to persist in a 'latent' state in the liver and in peripheral blood mononuclear cells. 3, 4 However, there are no data about the percentage of patients who keep a transcriptionally active HBV genome for years or decades after complete clinical and serological recovery from acute hepatitis. In these patients, immunosuppression and loss of recipient B and T cell repertoire during allo-HSCT may lead to viral reactivation with reappearance of HBsAg after a gradual loss of anti-HBs; this has been termed 'reverse seroconversion'. To further characterize the risk of HBV reactivation in allo-HSCT recipients with resolved HBV infection, we investigated consecutive serum samples from six anti-HBs and anti-HBc-positive patients after allo-HSCT for the presence of HBV-DNA and for serologic markers of HBV infection.
Methods and patients

Patients
From 1998 to 2002, six patients with anti-HBs and antiHBc antibodies (four males, two females; median age 52.5 years, range 41-59 years) underwent allo-HSCT at the Department of Internal Medicine I of the University Hospital Regensburg, Germany (Table 1 ). All patients had cleared acute HBV infection prior to diagnosis of their haematological disease. Serum samples were taken prior to allo-HSCT and every 2-4 months during a median followup of 30 months (range 15-53). Serum samples were processed immediately, or stored at À201C until use.
Serology
HBsAg, HBeAg, anti-HBs, anti-HBc, anti-HBc-IgM and anti-HBe were tested with commercial microparticle enzyme immunoassays (AXSYM HBsAgt, AXSYM HBet, AXSYM AUSABt, AXSYM COREt, AXSYM CORE-Mt, AXSYM Anti-HBet; Abbott Laboratories, Abbott Park, IL, USA) according to the manufacturer's instructions.
HBV-DNA
HBV-DNA was isolated from serum with the QIAmpt blood kit (Qiagen, Hilden, Germany) and quantitatively measured using a kinetic fluorescence detection system (TaqMan PCR) as previously described. 5 To increase the sensitivity of this assay (to lower the detection limit below 100 HBV DNA copies/ml serum), each PCR was performed in 10 parallel reactions.
Sequencing
The HBV precore region (codons 1-29, according to nucleotide positions 1814-1900) was analysed as described previously. 6 The sequence of the HBV S gene was determined from three widely overlapping partial sequences. 7 Dye terminator cycle sequencing was performed with a 373A ABI automated sequencer (PE Applied Biosystems Inc., Foster City, CA, USA).
Results
Reverse seroconversion was observed in three patients (ID 1,2,4) at 14, 22 and 12 months after allo-HSCT, respectively (Table 1) . HBV-DNA was detectable in serum prior to reverse seroconversion, and HBV-DNA concentration started to increase about 2-4 months prior to HBsAg reappearance ( Figure 1 ). HBsAg became positive when HBV-DNA levels rose above 10 4 copies/ml serum. In patient 1, reverse seroconversion was associated with a mild to moderate elevation of transaminases (ALT peak level: seven-fold normal value). Testing at 18 months after allo-HSCT (4 months after reverse seroconversion) showed spontaneous HBsAg clearance in this patient. He remained HBsAg negative until his death from relapsed leukaemia 53 months after allo-HSCT. Patients 2 and 4 had no relevant increase in transaminases and became HBsAg and HBeAg positive carriers with persistently high levels of viral DNA (up to 10 10 copies/ml). One patient (ID 5) was repeatedly positive for HBV-DNA; he had no clinical evidence of hepatitis or reverse seroconversion, and the anti-HBs-titre declined from 41000 to 135 IU/l after 22 months.
Two patients (ID 3,6) remained HBV-DNA negative, did not have hepatitis clinically and had no reverse seroconversion but showed loss of anti-HBc. In patient 3, the antiHBs-titre declined from 41000 to 299 IU/l at the patient's death from relapsed leukaemia, 25 months after allo-HSCT. In patient 6, anti-HBs-titres changed from 265 IU/l prior to HSCT to 41000 IU/l at 8 months to 207 IU/l at 15 months after allo-HSCT (donor was vaccinated against HBV).
Sequence analysis of the HBsAg and precore region derived from the four HBV-DNA-positive patients showed no relevant mutations. HBV reactivation in allogeneic stem cell recipients A Knöll et al
Discussion
The present study of six patients with resolved HBV infection showed a much higher incidence of reverse seroconversion after allo-HSCT (50%) than the reported risk of 14-20% from previous investigations. 8, 9 This difference could be explained by a variety of reasons: (i) In our study -as in others -the risk had to be estimated from a small number of available allo-HSCT patients with pretransplant anti-HBs and anti-HBc antibodies; (ii) detection of HBV reactivation might be missed in the absence of clinical symptoms. In the present study, only one of three patients with reverse seroconversion had biochemical signs of liver damage. In contrast, the vast majority of reported patients with reverse seroconversion after allo-HSCT were identified only because they developed clinical hepatitis (Table 2) ; (iii) changes in immunosuppressive therapy strategies, for example, the use of mycophenolate mofetil as given to the majority of our patients, could influence risk of HBV reactivation; (iv) HBV reactivation has been reported as late as 2 years after complete clearance of anti-HBs, anti-HBc and anti-HBe 15 or 51 months after HSCT and 40 months after cessation of immunosuppressive therapy, 20 suggesting that HBV reactivation was due not only to immunosuppression but also to reconstitution with donor-derived naive immunity against HBV. Therefore, the risk of reactivation of latent HBV could increase in long-term allo-HSCT survivors and would be underestimated in studies with a short follow-up.
Using a highly sensitive TaqMan PCR assay with a detection limit of 10-100 HBV-DNA copies/ml serum, we were able to identify all three patients early who later had reverse seroconversion. During early follow-up, they had low-level viraemia and there was a 2 log increase in HBV-DNA concentration starting 2-4 months prior to reverse seroconversion. Similarly, Sakamaki et al. 18 reported one patient who was HBV-DNA positive by real-time PCR with 89 copies/ml serum (branched DNA assay negative) about 10 months after allo-HSCT. After an additional 12 months he developed fatal liver damage with reverse seroconversion and HBV-DNA concentrations of 2 Â 10 6 copies/ml. Interestingly, we identified one patient who HBV reactivation in allogeneic stem cell recipients A Knöll et al remained HBsAg negative but also had low-level viraemia. Therefore, 66% of our patients (4/6) showed evidence of viral replication by positive HBV-DNA PCR in serum.
One reported risk factor for HBV reactivation with clinical flare is chronic graft-versus-host-disease (cGVHD). 9 In the present study, four patients had extensive cGVHD, and three of them showed reverse seroconversion. Only one patient with extensive cGVHD showed no evidence of viral reactivation (ID 6): she was the only recipient of stem cells from a vaccinated donor, but also the patient with the shortest follow-up (15 months). The inclusion of glucocorticoids in the immunosuppressive regimen might be an independent risk factor for HBV reactivation, probably due to the presence of a specific glucocorticoid response element in the HBV genome. 21 HBV-associated liver disease after allo-HSCT is often temporary and not serious, but fatal liver damage has been reported in some cases. 16, 18 In the three patients with reverse seroconversion reported herein, there was mild hepatitis in only one patient, followed by spontaneous clearance of HBsAg. The other two patients had no biochemical signs of liver damage but became chronic carriers with high-level HBV viraemia. In addition to the long-term risks associated with the HBV carrier status, these patients could become a source of HBV infection for the severely immunocompromised patients in the HSCT setting and for other close contacts. There is one case of HBV reactivation after allo-HSCT that was diagnosed after the patient's spouse acquired HBV. 12 Therefore, there might be a significant risk for sexual partners of such patients and this may be adequate justification for looking for HBV reactivation in all anti-HBc-positive patients who undergo allo-HSCT.
We sequenced the HBV precore region in all four patients with HBV viraemia because some studies showed a higher incidence of liver dysfunction in HSCT recipients with precore mutations. [22] [23] [24] There were no mutations in the HBV precore region derived from our patients, who had no severe liver damage. Sequencing of the HBV S gene also showed no relevant mutations, suggesting that HBV reactivation was indeed due to immunosuppression and/or reconstitution with donor-derived naive immunity against HBV and not to HBsAg escape variants of the virus. The nucleoside analogue lamivudine (3 0 -thiazytidine) has significant clinical activity against HBV 25 and has been used successfully for prophylactic and therapeutic treatment of HBV reactivation after HSCT. 26 However, mutations in the YMDD motif of the HBV polymerase can confer resistance to lamivudine, especially after longterm treatment. 27 In our study, the only patient who received lamivudine (ID 4) had to stop it after 8 weeks (without influence on viral load) because of severe persistent diarrhoea. Sequence analysis of the YMDD motif of the HBV polymerase (deduced from an alternative reading frame within the HBV S gene region) showed no mutations before, during or after lamivudine treatment in this patient.
Published guidelines from the Centers of Disease Control, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation for the prevention of infections among HSCT recipients do not allude to HBV reactivation. 28 In the general population, the prevalence of anti-HBs and antiHBc indicating resolved HBV infection is 5-20% in the US 29 and about 7% in Germany, 30 respectively. As HSCT is performed for an increasing variety of malignant or genetic disorders, a significant number of HSCT patients are at risk for HBV reactivation. The present study suggests vaccination of anti-HBs negative donors prior to allo-HSCT as a possible approach to prevent HBV reactivation in recipients with resolved HBV infection. Further studies are needed to investigate whether an adoptive immune transfer by anti-HBs positive donor lympho-haematopoietic stem cells may lead to improved and sustained immunity against HBV. In conclusion, allo-HSCT recipients with resolved HBV infection are at significant risk for HBV reactivation with or without clinical hepatitis. HBV reactivation might occur very late (months to years) after transplantation and the serologic pattern might not be typical. Careful monitoring of the post-transplant HBV-DNA levels -as recommended by Strasser & McDonald 2 for HBsAg-positive HSCT recipients -is also warranted in recipients with resolved HBV infection.
